期刊
MEDICAL HYPOTHESES
卷 73, 期 5, 页码 662-663出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.mehy.2009.04.046
关键词
-
资金
- National Basic Research Program (973 Project) of China [2007CB507406]
- National Natural Science Foundation of China [30572341]
- Tsinghua-Yue-Yuen Medical Sciences Fund [THYY-20070008]
Emerging evidences indicate that elevated cholesterol and triglyceride levels precede Alzheimer's disease (AD) pathology. High caloric intake based on saturated fat raises hyperlipidaemia and also promotes AD pathology. As a result, strategy that limits the absorption of dietary fat and attenuates hyperlipidemia could be a useful medication for protective treatment of AD. As an active site-directed inhibitor of digestive lipases, orlistat effectively reduces dietary fat absorption and decreases total cholesterol and triglyceride levels in plasma. Orlistat also potently inhibits lipoprotein lipase, monoacylglycerol lipase and diacylglycerol lipase, which are also involved in AD causation. Taken together, orlistat inhibits lipases activities, thereby reduces dietary fat intake and ameliorates hyperlipidemia, which indicates a therapeutic potential of orlistat in protecting against AD pathology. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据